Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3526 |
|
| Actual shortage: | 229 (6%) | |
| Anticipated shortage: | 3 (0%) | |
| Avoided shortage: | 11 (0%) | |
| Resolved: | 3283 (93%) | |
Discontinuation Reports |
366 |
|
| To be discontinued: | 24 (7%) | |
| Discontinued: | 342 (93%) | |
| Reversed: | 0 (0%) | |
Late reports |
143 (4%) |
|
Overdue reports |
32 (13%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-SERTRALINE | 100MG | CAPSULE | Resolved | 2018-05-08 | 2018-05-29 | 48860 |
| APO-SERTRALINE | 25MG | CAPSULE | Resolved | 2018-05-15 | 2018-06-12 | 49374 |
| APO-SERTRALINE | 25MG | CAPSULE | Resolved | 2018-07-16 | 2018-08-31 | 55847 |
| APO-SERTRALINE | 100MG | CAPSULE | Resolved | 2018-08-09 | 2018-11-27 | 57820 |
| APO-SERTRALINE | 50MG | CAPSULE | Resolved | 2019-04-04 | 2020-03-27 | 80539 |
| APO-SERTRALINE | 25MG | CAPSULE | Resolved | 2019-04-24 | 2019-05-31 | 82334 |
| APO-SERTRALINE | 100MG | CAPSULE | Resolved | 2019-05-29 | 2020-03-02 | 85161 |
| APO-SERTRALINE | 50MG | CAPSULE | Resolved | 2019-06-05 | 2020-03-09 | 85613 |
| APO-SERTRALINE | 25MG | CAPSULE | Resolved | 2019-07-03 | 2019-09-06 | 88365 |
| APO-SERTRALINE | 50MG | CAPSULE | Resolved | 2020-04-15 | 2020-05-11 | 112195 |
| APO-SERTRALINE | 50MG | CAPSULE | Resolved | 2021-03-05 | 2021-03-15 | 135174 |
| APO-SERTRALINE | 25MG | CAPSULE | Resolved | 2021-10-01 | 2021-12-06 | 146514 |
| APO-SERTRALINE | 50MG | CAPSULE | Resolved | 2022-12-09 | 2022-12-23 | 177597 |
| APO-SERTRALINE | 50MG | CAPSULE | Resolved | 2023-02-16 | 2023-03-23 | 185004 |
| APO-SERTRALINE | 25MG | CAPSULE | Resolved | 2023-09-15 | 2023-10-06 | 204420 |
| APO-SERTRALINE | 25MG | CAPSULE | Resolved | 2023-11-10 | 2024-01-19 | 209945 |
| APO-SERTRALINE | 100MG | CAPSULE | Resolved | 2023-11-17 | 2024-01-12 | 210683 |
| APO-SERTRALINE | 25MG | CAPSULE | Resolved | 2024-03-15 | 2024-05-03 | 222481 |
| APO-SERTRALINE | 100MG | CAPSULE | Resolved | 2024-03-27 | 2024-04-12 | 223540 |
| APO-SERTRALINE | 100MG | CAPSULE | Resolved | 2024-05-24 | 2024-07-05 | 228786 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
| APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
| APO-BROMAZEPAM | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
| APO-BROMAZEPAM | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
| APO-BROMAZEPAM | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
| APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
| APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
| APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
| APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41047 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |